Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
Lipika Goyal(Stanford Medicine), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Hui Zheng(Harvard University), Supriya K. Saha(Diamond Harbour Women's University), Vikram Deshpande(Beth Israel Deaconess Medical Center), Kenneth K. Tanabe(Harvard University), Theodore S. Hong(Massachusetts General Hospital), A. John Iafrate(Massachusetts General Hospital), Cristina R. Ferrone(Cedars-Sinai Medical Center), Janet E. Murphy(Harvard University), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Valentina Nardi(Biopredic (France)), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Dawn Q. Chong(National Cancer Centre Singapore), Nabeel Bardeesy(Broad Institute), Eunice L. Kwak(Harvard University), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Aparna Govindan(University of Miami), Rahul A. Sheth(Massachusetts General Hospital), Jill N. Allen(Harvard University), Jason E. Faris(Royal Marsden NHS Foundation Trust)
Cited by 135
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k